01 Increasing Focus on Functional Cure Strategies The hepatitis B therapeutics market is shifting from long-term viral suppression toward treatment approaches that aim for a functional cure, characterized by sustained control of hepatitis B virus after treatment and loss of hepatitis B surface antigen. This is encouraging research into therapies that directly target viral replication and persistence while also stimulating or restoring effective host immune responses. The development pipeline is therefore becoming more focused on achieving deeper and potentially treatment-free disease control. In 2025, clinical development programs continued to evaluate combinations of direct-acting antiviral and immune-modulating approaches designed to increase the likelihood of hepatitis B surface antigen loss.
02 Expansion of Combination and Novel Mechanism Therapies The therapeutic landscape is increasingly diversifying beyond established nucleos(t)ide analogues and pegylated interferon. Investigational approaches include capsid assembly modulators, small interfering RNA, antisense oligonucleotides, entry inhibitors, and immune-based therapies. These approaches are being evaluated individually and in combinations to address different stages of the hepatitis B viral lifecycle and improve treatment outcomes. In 2025, clinical research continued to evaluate combinations of small interfering RNA, capsid assembly modulators, and immune-modulating agents as potential components of future hepatitis B treatment regimens.
01 Large Global Burden of Chronic Hepatitis B The substantial number of people living with chronic hepatitis B creates a large and persistent treatment population. Chronic infection can progress to cirrhosis, liver failure, and hepatocellular carcinoma, creating continued demand for antiviral therapy and long-term disease management. Improved diagnosis and linkage to care can further expand the number of patients receiving treatment.
01 Long-Term Treatment Requirements With Limited Treatment Cessation Current antiviral therapies can effectively suppress hepatitis B virus replication but generally do not eliminate the persistent viral reservoir responsible for chronic infection. Many patients therefore require prolonged or lifelong treatment to maintain viral suppression. The need for long-term therapy increases cumulative treatment costs and can create challenges related to adherence and continued clinical monitoring.
01 Expansion of Personalized Treatment and Combination Regimens Creates New Opportunities Advances in understanding patient response and disease characteristics are creating opportunities to develop more personalized hepatitis B treatment strategies. These approaches could improve viral suppression, treatment durability, and long-term disease management while expanding the range of therapeutic options available to patients.
01 Difficulty of Eliminating Persistent Viral Reservoirs Hepatitis B presents a major therapeutic challenge because covalently closed circular DNA can persist within infected liver cells even when circulating viral levels are effectively suppressed. This viral persistence makes complete eradication difficult and contributes to the risk of disease recurrence after treatment interruption. Developing therapies capable of targeting this reservoir without causing unacceptable toxicity remains a central challenge for drug developers.
June 2026 Gilead Sciences expanded its hepatitis B therapeutics portfolio by advancing next-generation antiviral therapies and combination treatment approaches designed to improve viral suppression, enhance patient outcomes, and support functional cure research for chronic hepatitis B infection.
April 2026 Johnson & Johnson expanded its infectious disease treatment portfolio by strengthening research initiatives focused on innovative hepatitis B therapies, including antiviral and immune-based treatment strategies aimed at improving long-term disease management.
January 2026 Roche expanded its virology and immunology pipeline by advancing novel therapeutic approaches for chronic hepatitis B, focusing on immune modulation, viral control, and improved treatment outcomes for patients requiring long-term management.
October 2025 GSK expanded its infectious disease portfolio by developing advanced hepatitis B treatment approaches, including combination therapies designed to target different stages of the hepatitis B virus lifecycle and improve therapeutic effectiveness.